SEARCH

SEARCH BY CITATION

Dedication

  1. Dedication
  2. References

This article is dedicated to Professor Bruno Rotoli, who was an irreplaceable teacher for our work.

References

  1. Dedication
  2. References
  • Aloj, L., Caraco, C., Jagoda, E., Eckelman, W.C. & Neumann, R.D. (1999) Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Research, 59, 47094714.
  • Haioun, C., Itti, E., Rahmouni, A., Brice, P., Rain, J.D., Belhadj, K., Gaulard, P., Garderet, L., Lepage, E., Reyes, F. & Meignan, M. (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood, 106, 13761381.
  • Jerusalem, G., Beguin, Y., Najjar, F., Hustinx, R., Fassotte, M.F., Rigo, P. & Fillet, G. (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Annals of Oncology, 12, 825830.
  • Kuo, P.H., McClennan, B.L., Carlson, K., Wilson, L.D., Edelson, R.L., Heald, P.W. & Girardi, M. (2008) FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Molecular Imaging and Biology, 10, 7481.
  • Leskinen-Kallio, S., Ruotsalainen, U., Någren, K., Teräs, M. & Joensuu, H. (1991) Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma: a PET study. Journal of Nuclear Medicine, 32, 12111218.
  • Mikhaeel, N.G., Hutchings, M., Fields, P.A., O’Doherty, M.J. & Timothy, A.R. (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Annals of Oncology, 16, 15141523.
  • Pangalis, G.A. & Tsavaris, N.B. (1986) Glucose-6-phosphatase activity of Reed-Sternberg and Hodgkin cells. Hematological Oncology, 4, 261266.
  • Schoder, H., Noy, A., Gonen, M., Weng, L., Green, D., Erdi, Y.E., Larson, S.M. & Yeung, H.W. (2005) Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 23, 46434651.
  • Tang, B., Douglas-Nikitin, V., Balon, H., Wong, C.O., Khong, P.L. & Wong, C.Y. (2009) Exceptionally low metabolic activity in aggressive peripheral T-cell lymphoma. Nuclear Medicine Communications, 30, 838840.
  • Whitcomb, C.C., Olivella, J.E. & Byrne, Jr, G.E. (1983) T-cell lymphoma-leukemia. Pathologic observations in three cases. Cancer, 52, 12021209.